| scholarly article | Q13442814 |
| P2093 | author name string | Peter L Collins | |
| Alexander C Schmidt | |||
| Anne Schaap-Nutt | |||
| Henrick Schomacker | |||
| P2860 | cites work | Mutations in the C, D, and V open reading frames of human parainfluenza virus type 3 attenuate replication in rodents and primates | Q45747093 |
| Pediatric hospitalizations for croup (laryngotracheobronchitis): biennial increases associated with human parainfluenza virus 1 epidemics | Q45759130 | ||
| Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children < 5 years old. | Q45764064 | ||
| Protective effect of antibody to parainfluenza type 1 virus | Q45824738 | ||
| Parainfluenza virus bronchiolitis. Epidemiology and pathogenesis | Q45837485 | ||
| Prospective population-based study of viral lower respiratory tract infections in children under 3 years of age (the PRI.DE study). | Q47925908 | ||
| Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. | Q50518501 | ||
| Respiratory viruses in laryngeal croup of young children. | Q54537305 | ||
| Role of respiratory viruses in childhood mortality | Q64382524 | ||
| Clinical features of infection with hemadsorption viruses | Q78614269 | ||
| Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease | Q22008612 | ||
| Glucocorticoids for croup | Q24235015 | ||
| Nebulized epinephrine for croup in children | Q24236682 | ||
| The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta promoter | Q24558779 | ||
| Parainfluenza viruses | Q24682952 | ||
| The C proteins of human parainfluenza virus type 1 block IFN signaling by binding and retaining Stat1 in perinuclear aggregates at the late endosome | Q27311445 | ||
| Viruses and interferon: a fight for supremacy | Q28220397 | ||
| Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures | Q29618978 | ||
| Immunohistochemical assessment of respiratory viruses in necropsy samples from lethal non-pandemic seasonal respiratory infections | Q30394215 | ||
| Differential regulation of type I interferon and epidermal growth factor pathways by a human Respirovirus virulence factor | Q33508793 | ||
| Scanning independent ribosomal initiation of the Sendai virus Y proteins in vitro and in vivo | Q33559628 | ||
| Human parainfluenza virus type 2 V protein inhibits interferon production and signaling and is required for replication in non-human primates | Q33653692 | ||
| Growth restriction of an experimental live attenuated human parainfluenza virus type 2 vaccine in human ciliated airway epithelium in vitro parallels attenuation in African green monkeys | Q33748766 | ||
| Respiratory virus pneumonia after hematopoietic cell transplantation (HCT): associations between viral load in bronchoalveolar lavage samples, viral RNA detection in serum samples, and clinical outcomes of HCT. | Q33785773 | ||
| Inhibition of STAT 1 phosphorylation by human parainfluenza virus type 3 C protein | Q33843169 | ||
| Recombinant human parainfluenza virus type 2 with mutations in V that permit cellular interferon signaling are not attenuated in non-human primates. | Q34101229 | ||
| Human parainfluenza virus type 4 is incapable of evading the interferon-induced antiviral effect | Q34142854 | ||
| Progress in the development of human parainfluenza virus vaccines | Q34209872 | ||
| The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion | Q34234077 | ||
| Detection of respiratory viruses and the associated chemokine responses in serious acute respiratory illness | Q34477691 | ||
| The C proteins of human parainfluenza virus type 1 limit double-stranded RNA accumulation that would otherwise trigger activation of MDA5 and protein kinase R | Q34529862 | ||
| Paramyxovirus strategies for evading the interferon response | Q34985852 | ||
| Identification of human parainfluenza virus type 2 (HPIV-2) V protein amino acid residues that reduce binding of V to MDA5 and attenuate HPIV-2 replication in nonhuman primates | Q35076577 | ||
| Immunology of viral respiratory tract infection in infancy | Q35131864 | ||
| Loss of V protein expression in human parainfluenza virus type 1 is not a recent event | Q35233276 | ||
| Weapons of STAT destruction. Interferon evasion by paramyxovirus V protein | Q35988020 | ||
| Local production of inflammatory mediators during childhood parainfluenza virus infection. | Q36160075 | ||
| The cDNA-derived investigational human parainfluenza virus type 3 vaccine rcp45 is well tolerated, infectious, and immunogenic in infants and young children | Q36190502 | ||
| Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children | Q36433111 | ||
| Interferon signalling network in innate defence | Q36471845 | ||
| Pathological changes in virus infections of the lower respiratory tract in children | Q36552154 | ||
| The parainfluenza virus type 1 P/C gene uses a very efficient GUG codon to start its C' protein | Q36693615 | ||
| Human parainfluenza virus type 2 V protein inhibits genome replication by binding to the L protein: possible role in promoting viral fitness | Q36747923 | ||
| Role of interferon in the replication of human parainfluenza virus type 1 wild type and mutant viruses in human ciliated airway epithelium | Q36845674 | ||
| Human parainfluenza virus type 1 C proteins are nonessential proteins that inhibit the host interferon and apoptotic responses and are required for efficient replication in nonhuman primates | Q36898701 | ||
| Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: contributions of the individual proteins to host immunity | Q36919535 | ||
| Human genetic factors and respiratory syncytial virus disease severity | Q36943137 | ||
| Symptomatic parainfluenza virus infections in children undergoing hematopoietic stem cell transplantation | Q37074844 | ||
| The C proteins of human parainfluenza virus type 1 (HPIV1) control the transcription of a broad array of cellular genes that would otherwise respond to HPIV1 infection | Q37099848 | ||
| Infection and maturation of monocyte-derived human dendritic cells by human respiratory syncytial virus, human metapneumovirus, and human parainfluenza virus type 3 | Q37158039 | ||
| Human parainfluenza virus infection of the airway epithelium: viral hemagglutinin-neuraminidase regulates fusion protein activation and modulates infectivity. | Q37232820 | ||
| The regulation of type I interferon production by paramyxoviruses. | Q37585325 | ||
| Infection of ciliated cells by human parainfluenza virus type 3 in an in vitro model of human airway epithelium | Q37743793 | ||
| The relationship between respiratory viral loads and diagnosis in children presenting to a pediatric hospital emergency department | Q38414055 | ||
| The histopathology of fatal untreated human respiratory syncytial virus infection | Q38435017 | ||
| Select paramyxoviral V proteins inhibit IRF3 activation by acting as alternative substrates for inhibitor of kappaB kinase epsilon (IKKe)/TBK1. | Q38531766 | ||
| The complete sequence of a human parainfluenzavirus 4 genome | Q38613005 | ||
| Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses | Q39272631 | ||
| Limited entry of adenovirus vectors into well-differentiated airway epithelium is responsible for inefficient gene transfer | Q39582545 | ||
| Degradation of STAT1 and STAT2 by the V proteins of simian virus 5 and human parainfluenza virus type 2, respectively: consequences for virus replication in the presence of alpha/beta and gamma interferons | Q39748096 | ||
| The Seattle Virus Watch. VI. Observations of infections with and illness due to parainfluenza, mumps and respiratory syncytial viruses and Mycoplasma pneumoniae | Q39945762 | ||
| Interferon production in children with respiratory syncytial, influenza, and parainfluenza virus infections | Q40146611 | ||
| Parainfluenza pneumonia in severe combined immunodeficiency disease | Q40211793 | ||
| Giant-cell pneumonia caused by parainfluenza virus | Q40211797 | ||
| mda-5, but not RIG-I, is a common target for paramyxovirus V proteins. | Q40218590 | ||
| Attenuating mutations in the P/C gene of human parainfluenza virus type 1 (HPIV1) vaccine candidates abrogate the inhibition of both induction and signaling of type I interferon (IFN) by wild-type HPIV1. | Q40272095 | ||
| Human parainfluenza virus type 4 infections: a report of 20 cases from 1998 to 2002. | Q40387336 | ||
| Parainfluenza virus infection of young children: estimates of the population-based burden of hospitalization | Q40399153 | ||
| Pathology of parainfluenza virus infection in patients with congenital immunodeficiency syndromes | Q40556922 | ||
| The V proteins of simian virus 5 and other paramyxoviruses inhibit induction of interferon-beta | Q40683472 | ||
| Giant cell pneumonia caused by parainfluenza type 3 in a patient with acute myelomonocytic leukemia | Q40796902 | ||
| The V protein of human parainfluenza virus 2 antagonizes type I interferon responses by destabilizing signal transducer and activator of transcription 2. | Q40808240 | ||
| RNA editing in the phosphoprotein gene of the human parainfluenza virus type 3 | Q41642850 | ||
| Human parainfluenza virus-associated hospitalizations among children less than five years of age in the United States | Q44332711 | ||
| Parainfluenza virus type 3: seasonality and risk of infection and reinfection in young children | Q44825036 | ||
| A prospective study of parainfluenza virus type 4 infections in children attending daycare | Q45369113 | ||
| Production of chemokines in the lungs of infants with severe respiratory syncytial virus bronchiolitis. | Q45496193 | ||
| The human parainfluenza virus type 3 (HPIV 3) C protein inhibits viral transcription | Q45696085 | ||
| Relationships among specific viral pathogens, virus-induced interleukin-8, and respiratory symptoms in infancy | Q45729843 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pathogenesis | Q372016 |
| human parainfluenza | Q2051533 | ||
| acute respiratory disease | Q97273244 | ||
| P304 | page(s) | 294-9 | |
| P577 | publication date | 2012-06-01 | |
| P1433 | published in | Current opinion in virology | Q26842394 |
| P1476 | title | Pathogenesis of acute respiratory illness caused by human parainfluenza viruses | |
| P478 | volume | 2 |
| Q30234336 | A Role for Neutrophils in Viral Respiratory Disease. |
| Q35040923 | Autologous antibody capture to enrich immunogenic viruses for viral discovery |
| Q40721939 | BCSH/BSBMT/UK clinical virology network guideline: diagnosis and management of common respiratory viral infections in patients undergoing treatment for haematological malignancies or stem cell transplantation. |
| Q39142106 | Characterization of a key residue for hyperfusogenic phenotype in human parainfluenza virus type 2 (hPIV-2) fusion glycoprotein. |
| Q57021778 | Clinical and Molecular Epidemiology of Human Parainfluenza Viruses 1-4 in Children from Viet Nam |
| Q63915269 | Complete Genome Characterization of Eight Human Parainfluenza Viruses from the Netherlands |
| Q38444340 | Detection of respiratory viruses in adult patients with perennial allergic rhinitis |
| Q58774142 | Discovery and genome characterization of three new Jeilongviruses, a lineage of paramyxoviruses characterized by their unique membrane proteins |
| Q57061670 | Exploring the impact of inoculum dose on host immunity and morbidity to inform model-based vaccine design |
| Q90186665 | Genetic diversity and evolutionary analysis of human respirovirus type 3 strains isolated in Kenya using complete hemagglutinin-neuraminidase (HN) gene |
| Q35125394 | Human parainfluenza virus type 3 (HPIV3) induces production of IFNγ and RANTES in human nasal epithelial cells (HNECs). |
| Q37425523 | Local production of CCL3, CCL11, and IFN-γ correlates with disease severity in murine parainfluenza virus infection |
| Q27331956 | Mode of parainfluenza virus transmission determines the dynamics of primary infection and protection from reinfection |
| Q30209342 | Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases |
| Q27312086 | Non-invasive Imaging of Sendai Virus Infection in Pharmacologically Immunocompromised Mice: NK and T Cells, but not Neutrophils, Promote Viral Clearance after Therapy with Cyclophosphamide and Dexamethasone |
| Q97530058 | Orally efficacious broad-spectrum allosteric inhibitor of paramyxovirus polymerase |
| Q36026277 | Parainfluenza 3-Induced Cough Hypersensitivity in the Guinea Pig Airways. |
| Q40590063 | Parainfluenza Virus Infection |
| Q40168808 | Parainfluenza Virus in the Hospitalized Adult |
| Q33810476 | Parainfluenza virus type 1 induces epithelial IL-8 production via p38-MAPK signalling |
| Q93138259 | Paramyxoviruses respiratory syncytial virus, parainfluenza virus, and human metapneumovirus infection in pediatric hospitalized patients and climate correlation in a subtropical region of southern China: a 7-year survey |
| Q92710888 | Receptor-mediated cell entry of paramyxoviruses: Mechanisms, and consequences for tropism and pathogenesis |
| Q35487966 | Relationships among dissemination of primary parainfluenza virus infection in the respiratory tract, mucosal and peripheral immune responses, and protection from reinfection: a noninvasive bioluminescence-imaging study |
| Q36080040 | Sendai Virus Induces Persistent Olfactory Dysfunction in a Murine Model of PVOD via Effects on Apoptosis, Cell Proliferation, and Response to Odorants |
| Q36987415 | Severe parainfluenza pneumonia in a case of transient hypogammalobulinemia of infancy. |
| Q64375183 | T Lymphocytes as Measurable Targets of Protection and Vaccination Against Viral Disorders |
| Q64974108 | Targeting Human Parainfluenza Virus Type-1 Haemagglutinin-Neuraminidase with Mechanism-Based Inhibitors. |
| Q31121121 | Use of laboratory and administrative data to understand the potential impact of human parainfluenza virus 4 on cases of bronchiolitis, croup, and pneumonia in Alberta, Canada |
Search more.